OBJECTIVE: To probe into the effects of oryzanol combined with fluoxetine hydrochloride on monoamine neurotransmitter and sleep quality in adolescent patients with depressive disorder. METHODS: A total of 174 adolescent patients with depressive disorder admitted into our hospital from Jun. 2018 to May 2021 were selected and divided into control group and observation group via random number table. Both groups were given psychological treatment

87 cases in the control group were treated with fluoxetine hydrochloride

the other 87 cases in the observation group were given fluoxetine hydrochloride combined with oryzanol. The clinical efficacy was evaluated and the incidences of adverse drug reactions were recorded in both groups after 6 months of treatment. The changes in Hamilton Depression Scale（HAMD） scores

Pittsburgh Sleep Quality Scale（PSQI） scores

inflammatory factors and monoamine neurotransmitter levels before and after treatment were analyzed. RESULTS: The total effective rate of the observation group was 88.51%（77/87）

which was higher than 72.41%（63/87） in the control group

with statistically significant difference（P<0.05）. After 3 months and 6 months of treatment

the HAMD and PSQI scores of the observation group were significantly lower than those of the control group

the interleukin 6（IL-6）

IL-1β and tumor necrosis factor α levels of the observation group were significantly lower than those of the control group

the norepinephrine

5-hydroxytryptamine and dopamine levels of the observation group were significantly higher than those of the control group

with statistically significant differences（P<0.05）. The incidence of adverse drug reactions of observation group was 11.49%（10/87）

compared with that of the control group（6.90%

6/87）

the difference was not statistically significant（P>0.05）. CONCLUSIONS: The efficacy of oryzanol combined with fluoxetine hydrochloride in the treatment of depressive disorder in adolescent is remarkable

which can inhibit the expression of inflammatory factors

promote the monoamine neurotransmitter levels

relieve depression and improve sleep quality

with good safety.